A comparison of Direct sequencing, Pyrosequencing, High resolution melting analysis, TheraScreen DxS, and the K-ras StripAssay for detecting KRAS mutations in non small cell lung carcinomas
Journal of Experimental & Clinical Cancer Research volume 31, Article number: 79 (2012)
It is mandatory to confirm the absence of mutations in the KRAS gene before treating metastatic colorectal cancers with epidermal growth factor receptor inhibitors, and similar regulations are being considered for non-small cell lung carcinomas (NSCLC) and other tumor types. Routine diagnosis of KRAS mutations in NSCLC is challenging because of compromised quantity and quality of biological material. Although there are several methods available for detecting mutations in KRAS, there is little comparative data regarding their analytical performance, economic merits, and workflow parameters.
We compared the specificity, sensitivity, cost, and working time of five methods using 131 frozen NSCLC tissue samples. We extracted genomic DNA from the samples and compared the performance of Sanger cycle sequencing, Pyrosequencing, High-resolution melting analysis (HRM), and the Conformité Européenne (CE)-marked TheraScreen DxS and K-ras StripAssay kits.
Results and conclusions
Our results demonstrate that TheraScreen DxS and the StripAssay, in that order, were most effective at diagnosing mutations in KRAS. However, there were still unsatisfactory disagreements between them for 6.1% of all samples tested. Despite this, our findings are likely to assist molecular biologists in making rational decisions when selecting a reliable, efficient, and cost-effective method for detecting KRAS mutations in heterogeneous clinical tumor samples.
At present, identifying targeted anticancer treatment suitable for a given patient requires the availability of accurate diagnostics. Diagnostic techniques therefore have a significant impact on patients’ survival and quality of life. In recent years, it has become apparent that certain types of tumors undergo mutations that either originate from the aberrant physiology of the tumor or are induced/selected by mutagenic cancer therapies[2–4]. Failure to detect mutations in important regulatory genes in tumor specimens may have serious consequences for the patients, because these alterations can significantly reduce the effectiveness of certain biological and cytotoxic therapies. Mutations in the KRAS oncogene are often found in human cancers. They are most common in pancreatic cancer, which can exhibit mutation rates of 80 - 90%. KRAS mutations are also observed in 40 – 50% of colorectal cancers and 10 - 30% of Non-Small Cell Lung Cancers (NSCLCs).
Recent studies have shown that some anticancer drugs are only effective against tumors in which the KRAS signaling pathway has not undergone oncogenic activation. These include the small-molecule epidermal growth factor receptor inhibitors erlotinib (Tarceva®) and gefitinib (Iressa®), which are used to treat NSCLC patients, and monoclonal antibody therapies such as cetuximab (Erbitux®) and panitumumab (Vectibix®), which are primarily used in the treatment of metastatic colorectal cancers (mCRC)[5–7]. According to the U.S. National Comprehensive Cancer Network (NCCN) guidelines from November 2008 (http://www.nccn.org/about/news/newsinfo.asp?NewsID=194) and recommendations of the American Society of Clinical Oncology (ASCO), screening of the status of the KRAS gene is mandatory when deciding whether or not a patient with colorectal cancer should receive anti-EGFR drugs. Similar rules are being considered for NSCLC where KRAS mutations have prognostic value for progressive disease in adenocarcinoma[9, 10].
There are multiple methods for detecting KRAS mutations in patient tissues, with varying analytical parameters. Individual methods need to be evaluated in terms of their sensitivity, specificity, and cost per analysis before they can be considered to meet acceptable gold standards in clinical practice. A standardized European quality assurance program for tests to detect mutations in KRAS was proposed at the Third International Congress of Pathology, held by the European Society of Pathology (ESP) in Barcelona in May 2008. This program is focused on achieving optimal accuracy and proficiency across the European Union. However, there are many methods in current use, some of which are only employed by individual laboratories and are not commercially available. These typically include sequencing assays and gel-based DNA conformation assays[13, 14]. Some of the commercial assays for detecting mutations in the KRAS gene have not yet been validated for clinical use (i.e.: Allele-specific oligonucleotide hybridization - Invigene®, KRAS mutation test kit - EntroGen®). At the time of writing, only the TheraScreen® kit sold by QiaGen, the KRAS LightMix® kit sold by TIB MolBiol, and the K-ras StripAssay® sold by ViennaLab had received the Conformité Européenne (CE) mark certifying them as being suitable for diagnostic use in the clinic under the terms of the European IVD Directive 98/79/EC.
In order to assess the specificity, sensitivity, cost, and working time of five frequently used methods for detecting mutations in KRAS, we performed parallel tests using DNA extracted from 131 frozen NSCLC tissue samples. The methods examined were Sanger cycle sequencing, Pyrosequencing, High-resolution melting analysis (HRM), and the CE-marked TheraScreen DxS and K-ras StripAssay kits. Our data demonstrate that there are important differences between these methods, which should be considered in routine clinical testing for KRAS mutations.
The experimental research presented in this manuscript was performed in compliance with the Helsinki Declaration according to the study ethics proposal approved by Ethical Board of Palacky University in Olomouc. Written informed consent was obtained from all patients for the use of the collected samples in the research projects which includes studies for publication of this report or any accompanied images.
Diagnosis of NSCLC was initially performed at the time of surgery and later confirmed from leftover by histological subtyping performed by experienced pathologist. All samples were found to contain more than 70% of tumour cells from at least 200 cells.
DNA extraction from cell lines and primary tumor samples
Genomic DNA was extracted from 131 frozen Non Small Cell Lung Cancer (NSCLC) tissue specimens removed from patients undergoing surgery for lung cancer. Tissue was snap frozen in liquid nitrogen immediately after surgery and stored at −80°C until analyzed. Cell lines with specific KRAS mutations were obtained from the American Tissue Culture Collection (ATCC, Rockville, MA) and cultured according to ATCC instructions. DNA extraction and purification was performed using the QIAquick (QIAGEN, Hilden, Germany) isolation kit according to manufacturer’s instructions; in each case examined, the five methods were tested against the same DNA isolate, so potential differences in percentage of tumor cells does not confound the method comparison. Concentrations of DNA samples were measured spectrophotometrically using a NanoDrop ND 1000 spectrophotometer (NanoDropTechnologies, Wilmington, USA).
Analyses were performed according to a blinded design, in which the experimentalist was not aware of the KRAS mutation status of any given sample. 131 NSCLC samples were analyzed using four methods: Direct sequencing, Pyrosequencing, and the TheraScreen DxS and K-ras StripAssay kits. Due to limited amount of tissue, only 116 samples from this group were also subjected to HRM analysis and 114 yielded usable data. Significance of the concordance of mutation detection with different methods for two categories (wildtype and mutant) was assessed by κ statistics (http://faculty.vassar.edu/lowry/kappa.html).
Direct sequencing method
Two primers were used to prepare amplicons for use in Sanger dideoxy termination sequencing: a forward (FW) primer, 5'AAA AGG TAC TGG TGG AGT ATT TGA, and a 3’ reverse (REV) primer, 5' TCA TGA AAA TGG TCA GAG AAA CC 3' (Generi-Biotech, Hradec Králové, Czech Republic). PCR was performed with a reaction volume of 50 μl in an MJ Research PTC-200 Peltier Thermal Cycler (Watertown, USA). The composition of the PCR reaction mixture was as follows: MgCl2 (3 mM, ThermoScientific, Waltham, USA), dNTPs (0.2 mM, ThermoScientific), ThermoStart DNA polymerase (2U, ThermoScientific), FW-primer (0.3 μM), REV-primer (0.3 μM), 1xPCR buffer, and between 10 ng and 100 ng of genomic DNA per reaction. The following amplification program was used: 95°C/15 min to activate the Taq polymerase; 35x (95°C/30 s, 58°C/30 s 72°C/30 s) for denaturation, annealing, and extension; and finally 75°C/5 min to finalize the extension, followed by cooling to 15°C. The PCR product was separated using a 2% agarose gel and purified using the QIAquick PCR purification kit (QIAGEN, Hilden, Germany). For each sample specimen, separate sequencing reactions were performed using the forward (FW) and reverse (REV) primers. The sequencing primers were internal to the amplicons from the previous PCR cycles: FW - 5' TTA ACC TTA TGT GTG ACA TGT TCT AA 3', REV - 5' AGA ATG GTC CTG CAC CAG TAAT 3'. Sequencing reactions were performed according to the manufacturer’s protocol in a 20 μl reaction volume containing 4 μl DTCS Quick Start kit (Beckman Coulter, Brea, USA), 1 μl (10 μM) of the FW or REV primer, 10 μl nuclease-free water, and 5 μl of 25x diluted template PCR product. After cleaning, precipitated DNA was diluted in SLS-formamide (Beckman Coulter, Brea, USA) and dideoxylabelled fragments were size-separated using an automated CEQ 8800 Genetic Analysis System (Beckman Coulter, Brea,USA) (Figure1). Sequence identification was performed using version 1.42 of the Chromas software package (Conor McCarthy, Southport, Australia). For all analyses, data obtained with the forward and reverse primers were combined and aligned to the consensus sequence obtained from the BLAST GenBank databasehttp://www.ncbi.nlm.nih.gov/nuccore/166706780?report=genbank.
In the pyrosequencing method for DNA sequence analysis[16, 17], inorganic phosphate released in the course of nucleotide incorporation serves as the initial substrate in a sequence of four successive enzymatic reactions. This result in the emission of light, which functions as a signal that is proportional to the number of nucleotides incorporated.
In this project, the PyroMark K-ras assay test (Biotage, Uppsala, Sweden) was used for primary amplification and pyrosequencing of both the 12th and the 13th codons of the KRAS oncogene (Figure2). The following amplification program was used: the mixture was heated at 95°C for 5 min, then subjected to 45 cycles of 95°C for 15 s, 57°C for 30 s, and 72°C for 15 s. It was then held at 72°C for 5 min, and finally cooled to and held at 4°C. The final concentrations of the PCR components were: 1x PCR buffer, 2 mM MgCl2, 0.125 mM dNTPs, 0.2 μM FW primer and 0.2 μM REV biotinylated primer, 1U of AmpliTaq polymerase (Perkin Elmer, Waltham, USA) and 2 ng/μl DNA template. Fifteen μl of the PCR product was run on a 1,5% agarose gel (Sigma-Aldrich, St. Louis, USA) to confirm successful amplification, and 100 ng of PCR products were sent to the EpigenDX company (Worcester, USA) to be analyzed using the PyroMark MD System and the Pyromark ID analysis Software with previously validated cut-off of 5%.
K-RAS TheraScreen DxS
The TheraScreen DxS KRAS Mutation Kits KR-21 and KR-22 (QiaGen, Hilden, Germany) are designed to detect six mutations in codon 12 (Gly > Ala, Asp, Arg, Cys, Ser, and Val) and one in codon 13 (Gly > Asp) of the KRAS oncogene. The primers used in the assay have two characteristic features: sequence-specific 3’ ends (which comprise the PCR-Amplification Refractory Mutation System, PCR-ARMS®) to identify specific mutations, and Real-time PCR-Scorpion® primer tags, which fluoresce when incorporated into double-stranded DNA (Figure3). The commercial test kit includes an internal reaction control and a synthetic control template. The degree of mutation of KRAS is calculated on the basis of the difference between the control reaction and the allele-specific reaction in terms of the number of cycles required for the fluorescence of the reaction mixture to exceed the background level (Δ-CT).
PCR reactions were performed according to the protocol recommended by the manufacturer (TheraScreen K-RAS Mutation Kit version DU001PE) using a LightCycler®480 II (Roche Applied Science, Penzberg, Germany), with a final reaction volume of 25 μl. An initial denaturation step at 95°C for 4 min was followed by 45 cycles of 95°C for 30 sec and 60°C for 1 min. Analysis was performed using a predefined absolute quantification algorithm implemented in the LightCycler Analysis Software 1.5.0 SP3 program (Roche Applied Science, Penzberg, Germany) and by visual inspection conducted by two different researchers.
The K-ras StripAssay REF 5–590 (ViennaLab Diagnostics GmbH, Vienna, Austria) detects the 10 most common mutations in the KRAS gene by using multiplex mutant-enriched PCR and reverse-hybridization of the amplification products to nitrocellulose test strips (oligonucleotides used in the subsequent hybridization reactions are synthesized as probes targeting 8 mutations in codon 12 of the KRAS gene (Gly > Ala, Arg, Asp, Cys, Ile, Leu, Ser, and Val) and two mutations in codon 13 (Gly > Asp and Gly > Cys). Specifically hybridized biotinylated oligonucleotides are visualized using streptavidin-alkaline phosphatase and colored substrates (Figure4).
The KRAS StripAssay was performed according to the manufacturer’s protocol (K-ras StripAssay™, ViennaLab Diagnostic GmbH, Vienna, Austria). Samples were diluted using deionized water to a concentration of 10 ng/μl. Five μl of diluted DNA was added to the multiplex PCR reaction with biotinylated primers, and PCR was conducted according to the manufacturer’s instructions. All of the incubation steps were performed using a PST-60 HL Plus thermoshaker (Biosan, Riga, Latvia) platform with the temperature set to 45°C. Scanning was performed using the EPSON Perfection V30 scanner (Epson America, Inc., Long Beach, USA) and bands were analyzed by StripAssayEvaluator software (ViennaLab, Vienna, Austria) and by visual inspection.
High resolution melting analysis
The high-resolution melting (HRM) assay is a platform for real time detection of mutations that can be used to identify small differences in DNA sequences, even in heterozygous samples, by assessing changes in the shape of their melting curve profiles compared to profiles generated using standard (wild-type) DNA (Figure5). The HRM assay was developed using a new family of DNA-intercalating dyes including SYTO 9, LC Green and LC GreenPLUS+ that display strong intercalation and even association with DNA.
HRM-PCR reaction components were used according to the instructions provided with the LightCycler® 480 II (Roche) instrument. The LC GreenPLUS (Idaho Technology, Salt Lake City, USA) intercalating dye was used, together with the primers FW-5'-AAA CTT GTG GTA GTT GGA GCT-3' (forward) and REV-5'-ATT AGC TGT ATC GTC AAG GCA-3' (reverse). The final concentrations of the components of the reaction mixture were: 1x PCR buffer, 2 mM MgCl2, 0.2 μM dNTP, 0.5x LC GreenPLUS, 0.2 U ThermoTaq polymerase (Thermo Scientific), and 0.3 μM FW and REV primer. The cycling and melting conditions were as follows: one cycle at 95°C for 15 min., followed by 45 cycles of 95°C for 10 s, 63°C for 10 s, and 72°C for 10 s. The sample was then melted by raising the temperature from 60°C to 95°C at a rate of 0.02 C/s. Mutations were analyzed using LightCycler Analysis Software 1.5.0 SP3 program (Roche Applied Science, Penzberg, Germany).
Five genotyping methods for determining the status of mutation of KRAS were assessed using frozen tissue from primary NSCLC tumor specimens. 131 DNA samples were analyzed with 4 of the methods (Direct sequencing, K-ras StripAssay, TheraScreen DxS, and Pyrosequencing), and 116 of these were also analyzed using the High resolution melting (HRM) technique. In the absence of a gold standard, we adopted a consensus method for assigning each sample’s mutation status. The results obtained and methodology used are shown in Table1.
As expected, the percentage of the DNA samples in which mutations were detected varied (from 20% to 5%) depending on the method of detection used. The Kras-StripAssay had the highest likelihood of referring a mutation in the KRAS locus, followed by TheraScreen DxS, HRM, Pyrosequencing, and Direct sequencing (Table2).
However, on the basis of our evaluation criteria (Table1), the most sensitive tool was the TheraScreen DxS kit (95%), followed by the K-ras StripAssay (90%), HRM (70%), Pyrosequencing (48%), and Sequencing (29%). The most specific tools were the TheraScreen DxS kit, Sequencing, and Pyrosequencing (100%), followed by HRM (98%) and the K-ras StripAssay (95%) (Table3).
The number of false positives and false negatives obtained with each method would change if one were to change the interpretation criteria. For example, if the K-ras StripAssay is taken to be the gold standard, then the false positives detected by this method would become false negatives detected by the other methods. To eliminate this potential ambiguity, we performed more tests to assess and compare the sensitivity thresholds of the tested methods. We used three ATCC cell lines whose KRAS mutation statuses are known and recorded in the COSMIC database: A549 (p.Gly12Ser), NCI-H620 (p.Gly12Val), and NCI-H2009 (p.Gly12Ala). We extracted sample DNA from the cell lines, measured its concentration by spectrophotometry, and then made dilution series of the DNA from the KRAS mutant cell lines in DNA from the NCI-H1975 KRAS wild-type cell line such that the mutant DNA comprised 25%, 20%, 15%, 10%, 5%, 1%, 0.5%, 0.25%, or 0.125% of the total KRAS DNA (Figure6).
At a mutant minority of 1%, only TheraScreen and StripAssay were capable of detecting mutations in KRAS, while other methods have detection limit at 10% (Pyrosequencing), and 25% (HRM and Sanger sequencing). Interestingly, in one technical replicate the mutation detected by the TheraScreen DxS kit in cell line A549 (p.Gly12Cys) was inconsistent with what was actually present. At a mutant minority of 0.5%, the TheraScreen DxS kit only detected mutation in the NCI-H620 cell line (p.Gly12Val); the K-ras StripAssay failed to yield any positive results when analyzed using the StripAssay Evaluator software, but was judged to have correctly detected a mutation in the NCI-H620 line on the basis of visual inspection. At a mutant minority of 0.25%, only the K-ras StripAssay yielded a positive result. Remarkably, the K-ras StripAssay was able to detect the mutation in the NCI-H2009 line (p.Gly12Ala) even at a mutant minority of 0.125%.
We have examined the ability of five different methods to detect mutations in the KRAS gene in 131 DNA samples. KRAS mutations were detected in 21 samples (16.0%), 107 samples were found to contain wild-type DNA (81.7%), and three yielded inconclusive results (2.2%) (Table1). Of the 21 samples in which mutation was detected by one or more methods, there were only four for which all five yielded a positive result (19.0%). Of the 95 wild-type samples analyzed by all five methods, concordance was observed in 87 (91.6%); overall, the five methods were in agreement with one-another for 78% of the samples examined. Excluding HRM, the four remaining analytical methods all generated positive results for 4 out of 21 samples found to be positive by one or more method (4.4%) and all generated negative results for 101 of 107 samples found to be negative by one or more method (94.4%), giving an overall agreement of 82%.
Our findings concerning the ability of these methods to detect mutations in KRAS are similar to those of Whitehall et al. (2009), who compared Dideoxy sequencing, HRM, the TIB Molbiol kit (Berlin, Germany), and the TheraScreen DxS (Manchester, UK) kit using DNA isolated from frozen colorectal cancer tissues. In their study, all five methods were found to be in concordance with regard to the KRAS mutation status of 66 of the 80 samples tested (83% agreement).
Both our results and those obtained by Whitehall show that a significant number of samples from colorectal tumor and NSCLC contain mixtures of KRAS wild-type and KRAS mutant cells, and that in many cases the percentage of mutant cells is below the threshold that can be detected by direct sequencing. This inherent heterogeneity of bioptic tumor tissues is an universal problem, albeit one that can be partially addressed by concentrating the tumor cells (e.g. by laser capture microdissection) before extracting their DNA. However, the fact that even a pure sample of tumor cells may contain large quantities of wild-type KRAS further complicates the selective identification of mutations in this gene. Consequently, it is desirable that methods for detecting KRAS mutations should be highly sensitive, and this point should be borne in mind when selecting a proper diagnostic method. Our study identified the TheraScreen DxS kit as having the best ability to detect KRAS mutations in clinical samples, followed by the K-ras StripAssay (Table4).
Our results also indicate that direct sequencing is only of limited utility when trying to detect mutations in the KRAS gene in cancer tissues, since this method only detected KRAS mutations in 6 of the 131 DNA samples tested, even though 21 were found to contain mutations by other methods. Though direct sequencing is still being advocated as KRAS genotyping method of choice, it missed 72% of all mutations in our cohort. Obviously, the sensitivity of the sequencing methods could be further improved by using laser microdissection, preferential preamplification, inclusion of both primary and metastatic tissues in the analysis, or by using clamping to suppress PCR amplification of the wild-type gene. However, we agree with Pinto et al. that Sanger sequencing (without the first steps of COLD-PCR) is currently outperformed by more sensitive techniques.
Pyrosequencing is easily capable of detecting PCR fragments that are 25–50 bp in length while longer fragments may pose a problem. However, this is not the case of detecting mutations in KRAS, because the most frequent mutations in this gene are adjacent, occurring in codons 12 and 13. It may even be advantageous to use short fragments when diagnosing mutations because DNA may be fragmented during the processing of clinical tissue samples. In accordance with results of others[27, 28], Pyrosequencing outperformed conventional sequencing for detecting KRAS mutations in samples with levels of mutant cells ranging from 5 to 25% (Table4) while quantification of mutated portion of DNA was not possible. This is probably due to preferential amplification of the mutated samples by the primers designed for the particular Biotage kit used. This shortcoming could be obviated by a better primer design or other modification of the kit and/or improvements in the interpretation algorithm[29, 30]. Promisingly, a massively parallel pyrosequencing system using nanoliter reaction volumes has yielded satisfying results in an interlaboratory comparison. While this probably represents the future of testing in predictive oncology, such systems are prohibitively costly for most laboratories at the present.
HRM proved to be the least expensive and the most rapid method, as it requires only standard real-time PCR reagents and a slightly prolonged PCR protocol. Despite the optimistic references from other laboratories, the analysis of the melting profiles in our hands remains less reliable than other methods, and even repeated testing of our reference DNA did not always yield consistent results. Because of this, the typing of two samples by this method was inconclusive. We may speculate with Do that treatment of DNA with uracil glycosylase or special step of DNA cleaning would help standardize the method and better its analytical parameters. Interestingly, HRM analysis identified mutations in the KRAS locus of two DNA samples (samples 31 and 32) for which none of the other methods detected any mutation (Table1). In keeping with the findings of other authors, we interpret these results as reflecting a tendency of HRM to generate false positives. However, it is possible that they reflect rare mutations outside codon 12 and 13 that destabilize heteroduplex DNA even in the presence of an excess of wild-type DNA. Although cost and time efficiency are important factors in clinical diagnosis, the reproducibility of the HRM method will need to be improved before it can be considered viable. This could potentially be done by changing primers, adding melting standards, spiking with oligonucleotides, or combination with SNaPshot.
The StripAssay was the most analytically sensitive test (Table2) of those we examined. On the basis of the results obtained with this method in the series of tests conducted with dilution series of mutant KRAS DNA (Figure6), one could even argue that samples 24 to 30 should be reassigned as mutants (Table2), thereby changing the false positive rate for the K-ras StripAssay to 0/128 and the false negative rate for TheraScreen DxS to 7/128. However, the interpretation of StripAssay results can be quite problematic for samples whose mutant DNA content is below 1% (see the result obtained with a mutant minority of 0.5% NCI-H620 in Figure6). Insofar, it was not tested in clinical studies what is a significance of fraction of mutated cells below 1%, regardless of the typing method used.
During time of submitting this article, company’s software was upgraded to follow more precisely the requirements of ISO15189 norm (scanner calibration standard was added and manual baseline correction feature was removed). It remains to be seen if such changes bring any improvement to diagnostic accuracy.
Of the methods examined in this study, the TheraScreen DxS kit was the fastest method and exhibited the highest sensitivity and specificity. However, it was also the most expensive method that is not free of false reactions. Specifically, the kit failed to detect the p.Gly13Cys mutation in sample 2 because it is not designed to detect this mutation. Although the frequency of the mutations that are not covered by the TheraScreen DxS test is very low and clinically not highly relevant, this nevertheless constitutes an inherent limitation of the kit. In addition, the precise allelic mutation detected by this kit in samples 3, 16, and 18 differed from the consensus result. While this could potentially be due to stochastic variation in the early events of PCR priming, there is no firm evidence to support this hypothesis. Although discrepancies in the precise identity of the mutation are not yet clinically relevant, and these results were not scored as errors in this study, this finding warrants caution when using the ARMS Scorpions assay in different diagnostic setups, where the type of mutation is important (e.g. when looking at the T790M and S768I activating mutations in EGFR genotyping). As discussed above, samples 24 to 30 gave positive results in the StripAssay but were negative when analyzed with the TheraScreen DxS kit, and they seem to have a mutant population in the clinically “grey area,” having less than 1% of the cells in the sample containing KRAS mutation. Ideally, their status should have been resolved by PCR amplicon cloning, followed by sequencing of the clones, digital PCR, or ultradeep sequencing. However, this approach is not practical for routine work and we did not have sufficient DNA to perform this experiment. Moreover, the low frequency of KRAS mutations in patient tumors have unknown clinical relevance, since all drug registration trials were performed using 1% of mutant KRAS cells as a low detection limit of the method.
The properties of the different methods examined in this work are summarized in Table5.
We agree with Tsiatis et al. that for research purposes more than one genotyping platform is necessary to reveal double mutations and to provide complementary data. In clinical settings, the most readily accessible NSCLC sample type is needle or brush biopsy, which is examined cytologically while resected, or biopsied tumors processed by formaldehyde fixation and paraffin embedding (FFPE). Proportion of FFPE samples from all samples usually reflects the best local practice and experience. Unfortunately, the FFPE process alters significantly the quality of DNA, and in many cases the DNA isolation from cytology smears yields higher quality albeit lower quantity of DNA.Very low quantity of available DNA isolated from cytological preparations was a major limiting factor in our comparative study, which we tried to overcome using frozen tissue from biobank, since it provides both high quality and quantity of DNA. Moreover, due to recent biobanking initiatives, we are more frequently facing situations, where the tumor molecular diagnostics is performed from frozen tissues. Of the 11 FFPE samples genotyped using both the StripAssay and TheraScreen, 5 samples could not be typed by at least one method, 2 samples were wildtype by both methods, 3 samples were mutant by both methods, and one sample was p.Gly12Asp by TheraScreen and wildtype by StripAssay. From one point of view, it could be argued that our genotyping results obtained using frozen samples are transferable to genotyping of FFPE samples because the mechanisms by which the methods work are not dependent on the nature of the input sample. On the other hand, it should be noted that improperly-performed paraffin embedding damages DNA and can favor methods that are more robust to variation in the amount and quality of the starting material (this would arguably disfavor TheraScreen because it requires eight PCR reactions whereas the other methods require only one equivalent reaction). It has been suggested that the issue of limited material for testing can be largely circumvented by using whole genome amplification techniques[39, 40], although the potentially biasing impact of the genome amplification techniques on low frequency somatic mutation genotyping is still not fully addressed. However, we suppose that our tests of kit performance on frozen tissue samples provide useful insights into their general utility and will be valuable for orchestrating genotyping efforts across molecular pathology laboratories.
The performance of five methods (Direct sequencing, Pyrosequencing, High resolution melting analysis, the TheraScreen DxS kit, and the K-ras StripAssay) for detecting mutations in the KRAS gene was compared using DNA extracted from 131 frozen NSCLC samples. The TheraScreen DxS kit was found to be the most effective, followed by the StripAssay kit. However, because of the heterogeneity of typical cancer tissue samples and the differences in the two methods’ mechanisms of action, there are still unsatisfactory numbers of discrepancies between these two ‘best’ methods, which failed to agree on 8 of the 131 specimens examined in this work. Nevertheless, our findings should facilitate the rational selection of methods for detecting mutations at the KRAS locus using heterogeneous clinical samples obtained from biopsies of cancer patients.
American Society of Clinical Oncology
American Tissue Culture Collection
European Society of Pathology
Formalin-fixed paraffin embedded
High resolution melting
Ki-ras2 kristen rat sarcoma viral oncogene homolog
Metastatic colorectal cancers
U.S. National Comprehensive Cancer Network
Non-small cell lung cancer
Single nucleotide polymorphism.
Jancik S, Drabek J, Radzioch D, Hajduch M: Clinical relevance of KRAS in human cancers. J Biomed Biotechnol. 2010, 2010: 150960. 1-13, Epub 2010 Jun 7
Lorigan P, Califano R, Faivre-Finn C, Howell A, Thatcher N: Lung cancer after treatment for breast cancer. Lancet Oncol. 2010, 11: 1184-1192. 10.1016/S1470-2045(10)70056-5.
Matesich SM, Shapiro CL: Second cancers after breast cancer treatment. Semin Oncol. 2003, 30: 740-748. 10.1053/j.seminoncol.2003.08.022.
Vasudevan KM, Garraway LA: AKT signaling in physiology and disease. Curr Top Microbiol Immunol. 2010, 347: 105-133. 10.1007/82_2010_66.
Hann CL, Brahmer JR: Who should receive epidermal growth factor receptor inhibitors for non-small cell lung cancer and when?. Curr Treat Options Oncol. 2007, 8: 28-37. 10.1007/s11864-007-0024-2.
Lievre A, Bachet JB, Boige V, Cayre A, Le CD, Buc E, et al: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008, 26: 374-379. 10.1200/JCO.2007.12.5906.
Patil DT, Fraser CR, Plesec TP: KRAS testing and its importance in colorectal cancer. Curr Oncol Rep. 2010, 12: 160-167. 10.1007/s11912-010-0099-y.
Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, et al: American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009, 27: 2091-2096. 10.1200/JCO.2009.21.9170.
Ludovini V, Bianconi F, Pistola L, Pistola V, Chiari R, Colella R, et al: Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations. Cancer Chemother Pharmacol. 2012, 69 (5): 1289-1299. 10.1007/s00280-012-1829-7.
Scoccianti C, Vesin A, Martel G, Olivier M, Brambilla E, Timsit JF, et al: Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort. Eur Respir J. 2012, 40 (1): 177-184. 10.1183/09031936.00097311. Epub 2012 Jan 20
van Krieken JH, Jung A, Kirchner T, Carneiro F, Seruca R, Bosman FT, et al: KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch. 2008, 453: 417-431. 10.1007/s00428-008-0665-y.
Pettersson E, Lundeberg J, Ahmadian A: Generations of sequencing technologies. Genomics. 2009, 93: 105-111.
Wojcik P, Kulig J, Okon K, Zazula M, Mozdzioch I, Niepsuj A, et al: KRAS mutation profile in colorectal carcinoma and novel mutation–internal tandem duplication in KRAS. Pol J Pathol. 2008, 59: 93-96.
Hayes VM, Westra JL, Verlind E, Bleeker W, Plukker JT, Hofstra RMW, et al: New comprehensive denaturing-gradient-gel-electrophoresis assay for KRAS mutation detection applied to paraffin-embedded tumours. Genes Chromosomes Cancer. 2000, 29: 309-314. 10.1002/1098-2264(2000)9999:9999<::AID-GCC1037>3.0.CO;2-F.
Lee JS: Alternative dideoxy sequencing of double-stranded DNA by cyclic reactions using Taq polymerase. DNA Cell Biol. 1991, 10: 67-73. 10.1089/dna.1991.10.67.
Gharizadeh B, Nordstrom T, Ahmadian A, Ronaghi M, Nyren P: Long-read pyrosequencing using pure 2'-deoxyadenosine-5'-O'-(1-thiotriphosphate) Sp-isomer. Anal Biochem. 2002, 301: 82-90. 10.1006/abio.2001.5494.
Ronaghi M, Uhlen M, Nyren P: A sequencing method based on real-time pyrophosphate. Science. 1998, 281: 363-365.
Angulo B, Garcia-Garcia E, Martinez R, Suarez-Gauthier A, Conde E, Hidalgo M, et al: A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma. J Mol Diagn. 2010, 12: 292-299. 10.2353/jmoldx.2010.090139.
Wittwer CT, Reed GH, Gundry CN, Vandersteen JG, Pryor RJ: High-resolution genotyping by amplicon melting analysis using LCGreen. Clin Chem. 2003, 49: 853-860. 10.1373/49.6.853.
Whitehall V, Tran K, Umapathy A, Grieu F, Hewitt C, Evans TJ, et al: A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. J Mol Diagn. 2009, 11: 543-552. 10.2353/jmoldx.2009.090057.
Gao J, Li YY, Sun PN, Shen L: Comparative analysis of dideoxy sequencing, the KRAS StripAssay and pyrosequencing for detection of KRAS mutation. World Journal of Gastroenterology. 2010, 16: 4858-4864. 10.3748/wjg.v16.i38.4858.
Liu A: Laser capture microdissection in the tissue biorepository. J Biomol Tech. 2010, 21: 120-125.
Zuo Z, Chen SS, Chandra PK, Galbincea JM, Soape M, Doan S, et al: Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. Mod Pathol. 2009, 22: 1023-1031. 10.1038/modpathol.2009.59.
Beau-Faller M, Legrain M, Voegeli AC, Guerin E, Lavaux T, Ruppert AM, et al: Detection of K-Ras mutations in tumour samples of patients with non-small cell lung cancer using PNA-mediated PCR clamping. Br J Cancer. 2009, 100: 985-992. 10.1038/sj.bjc.6604925.
Pennycuick A, Simpson T, Crawley D, Lal R, Santis G, Cane P, et al: Routine EGFR and KRAS Mutation analysis using COLD-PCR in non-small cell lung cancer. International Journal of Clinical Practice. 2012, 66: 748-752. 10.1111/j.1742-1241.2012.02961.x.
Pinto P, Rocha P, Veiga I, Guedes J, Pinheiro M, Peixoto A, et al: Comparison of methodologies for KRAS mutation detection in metastatic colorectal cancer. Cancer Genetics. 2011, 204: 439-446. 10.1016/j.cancergen.2011.07.003.
Tsiatis AC, Norris-Kirby A, Rich RG, Hafez MJ, Gocke CD, Eshleman JR, et al: Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. J Mol Diagn. 2010, 12: 425-432. 10.2353/jmoldx.2010.090188.
Ogino S, Kawasaki T, Brahmandam M, Yan LY, Cantor M, Namgyal C, et al: Sensitive Sequencing method for KRAS mutation detection by pyrosequencing. J Mol Diagn. 2005, 7: 413-421. 10.1016/S1525-1578(10)60571-5.
Chen G, Olson MT, O'Neill A, Norris A, Beierl K, Harada S, et al: A Virtual Pyrogram Generator to Resolve Complex Pyrosequencing Results. J Mol Diagn. 2012, 14: 149-159. 10.1016/j.jmoldx.2011.12.001.
Shen S, Qin D: Pyrosequencing data analysis software: a useful tool for EGFR, KRAS, and BRAF mutation analysis. Diagn Pathol. 2012, 7: 56-10.1186/1746-1596-7-56.
Gonzalez-Bosquet J, Calcei J, Wei JS, Garcia-Closas M, Sherman ME, Hewitt S, et al: Detection of Somatic Mutations by High-Resolution DNA Melting (HRM) Analysis in Multiple Cancers. PLoS ONE. 2011, 6 (1): e14522-10.1371/journal.pone.0014522.
Do HD, Dobrovic A: Dramatic reduction of sequence artefacts from DNA isolated from formalin-fixed cancer biopsies by treatment with uracil-DNA glycosylase. Oncotarget. 2012, 3: 546-558.
Weichert W, Schewe C, Lehmann A, Sers C, Denkert C, Budczies J, et al: KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology. J Mol Diagn. 2010, 12: 35-42. 10.2353/jmoldx.2010.090079.
Borras E, Jurado I, Hernan I, Gamundi MJ, Dias M, Marti I, et al: Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing. BMC Cancer. 2011, 11: 406-10.1186/1471-2407-11-406.
Vossen RH, Aten E, Roos A, Den Dunnen JT: High-resolution melting analysis (HRMA): more than just sequence variant screening. Hum Mutat. 2009, 30: 860-866. 10.1002/humu.21019.
Erali M, Palais R, Wittwer C: SNP genotyping by unlabeled probe melting analysis. Methods Mol Biol. 2008, 429: 199-206. 10.1007/978-1-60327-040-3_14.
Heideman DA, Lurkin I, Doeleman M, Smit EF, Verheul HM, Meijer GA, et al: KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA. J Mol Diagn. 2012, 14: 247-255. 10.1016/j.jmoldx.2012.01.011.
Riegman P, Dinjens W, Oomen M, Spatz A, Ratcliffe C, Knoxc K, et al: TVBaFrost 1: Uniting local Frozen Tumour Banks into a European Network: an overview. Eur J Cancer. 2006, 42: 2678-2683. 10.1016/j.ejca.2006.04.031.
Lim EH, Zhang SL, Li XL, Yap WS, Howe TC, Tan BP, et al: Using Whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage Non-small cell lung cancer (NSCLC). J Thorac Oncol. 2009, 4: 12-21. 10.1097/JTO.0b013e3181913e28.
van Eijk R, van Puijenbroek M, Chhatta AR, Gupta N, Vossen RH, Lips EH, et al: Sensitive and specific KRAS somatic mutation analysis on whole-genome amplified DNA from archival tissues. J Mol Diagn. 2010, 12: 27-34. 10.2353/jmoldx.2010.090028.
This research was supported by grants from the Ministry of Industry and Trade (MPO TIP FR-TI1/525), and the Ministry of Health of the Czech Republic (NT 13569 and NS 9959) and Internal Grant Agency of Palacky University (IGA UP VG911100371/32). Infrastructural part of this project (Institute of Molecular and Translational Medicine) was supported by the Operational Program “Research and Development for Innovations” (project CZ.1.05/2.1.00/01.0030).
The author(s) declare that they have no competing interests.
SJ: carried out the preparation of the samples and molecular genetic testing (pyrosequencing, TheraScreen assay, StripAssay, and HRM) and drafted the manuscript, JD: validated TheraScreen and StripAssay, interpreted HRM assays, revised the manuscript critically for important intellectual content, JB: carried out the molecular genetic testing (sequencing) and drafted the manuscript, YX: contributed in preparation of samples and carried out the molecular genetic testing analysis (pyrosequencing) and drafted the manuscript, MS: carried out the molecular genetic testing (TheraScreen assay) and drafted the manuscript, JK: surgically sampled patients and drafted the manuscript, VK: took care for patients and provided clinical data and drafted the manuscript, JŠ: carried out immunohistopathological testing to confirm disease status and drafted the manuscript, TT: carried out immunohistopathological testing to confirm disease status and drafted the manuscript, IG: took care for patients, provided and analysed clinical data, DR: concepted and designed the study, interpreted and analysed the data, MH: concepted and designed the study, interpreted and analysed the data, revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript.
Sylwia Jancik, Jiri Drabek contributed equally to this work.
Authors’ original submitted files for images
About this article
Cite this article
Jancik, S., Drabek, J., Berkovcova, J. et al. A comparison of Direct sequencing, Pyrosequencing, High resolution melting analysis, TheraScreen DxS, and the K-ras StripAssay for detecting KRAS mutations in non small cell lung carcinomas. J Exp Clin Cancer Res 31, 79 (2012). https://doi.org/10.1186/1756-9966-31-79